MAGE-A3 Antigen Specific Cancer Immunotherapeutic: Interim Phase II data

Interim data from a double-blind, placebo-controlled Phase II trial in 182 patients showed that MAGE-A3 ASCI vaccine missed the primary endpoint. At a median follow-up of 21 months, 30.3% of patients ...